Search

Search Constraints

You searched for: Author/Creator Yamaki, Kaori

Search Results

1. Biochemical control of the combination of cyclooxygenase‐2 inhibitor and 125I‐brachytherapy for prostate cancer: Post hoc analysis of an open‐label controlled randomized trial. (26th June 2020)

2. Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. (January 2019)

3. Comparison of disease‐specific quality of life in prostate cancer patients treated with low‐dose‐rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil. (10th August 2021)

4. Coverage of the external prostatic region by the hybrid method compared with the conventional method of prostate low‐dose‐rate brachytherapy: A randomized controlled study. (11th August 2020)

7. Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low‐dose‐rate brachytherapy for localized prostate cancer. (11th November 2021)

8. Linac-based fractionated stereotactic radiotherapy with a micro-multileaf collimator for large brain metastasis unsuitable for surgical resection. (17th June 2020)

9. Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low‐dose‐rate brachytherapy. (20th September 2022)

10. Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone. (28th October 2019)